1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
Global Attention-Deficit Hyperactivity Disorder (ADHD) Market: Size, Trends and Forecast (2019-2023)

Global Attention-Deficit Hyperactivity Disorder (ADHD) Market: Size, Trends and Forecast (2019-2023)

  • May 2019
  • 89 pages
  • ID: 5777735
  • Format: PDF
  • By Daedal Research

Summary

Table of Contents

Search Inside

Scope of the Report
The report entitled “Global Attention-Deficit Hyperactivity Disorder (ADHD) Market: Size, Trends and Forecast (2019-2023)” provides an in-depth analysis of the ADHD market including detailed description of market sizing and growth. The report provides an analysis of the global ADHD market by value, by segments and by distribution channel. The report also provides regional analysis of the ADHD market for the following regions: North America, Europe, Asia-Pacific, Middle East and Africa and Latin America.

Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall ADHD market has also been forecasted for the period 2019-2023, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

The major players dominating the attention-deficit hyperactivity disorder (ADHD) market are Johnson & Johnson, Pfizer Inc., Eli Lilly and Company and Takeda Pharmaceutical Company Limited (Shire Plc). The four companies have been profiled in the report providing their business overview, financial overview and business strategies.

Country Coverage
North America
Europe
Asia-Pacific
Middle East and Africa
Latin America

Company Coverage
Johnson & Johnson
Pfizer Inc.
Eli Lilly and Company
Takeda Pharmaceutical Company Limited (Shire Plc)

Executive Summary
ADHD is a complex neurological disorder which creates difficulty for a person in paying attention and in controlling their behavior. The symptoms of ADHD might vary from person to person, but the most common symptoms include restlessness, difficulty in paying attention, hyperactivity, frequent mood swings and difficulty in coping with stress. A person diagnosed with ADHD can suffer from the hyperactive-type, inattentive type or the combined type attention deficit disorder.

The most common factors which cause the attention-deficit hyperactivity disorder in people include exposure to environmental toxins such as high levels of lead at a young age, low birth weight, genes, brain injuries, etc. ADHD can be treated with the use of medication, therapy, education and training or a combination of these treatments.

ADHD has been segmented on the basis of medication type, therapy, age group and distribution channel. The two major kinds of medication for the treatment of ADHD are stimulants and non-stimulants. Various kinds of therapies for ADHD include behavior therapy, cognitive behavioral therapy, interpersonal therapy and family therapy. On the basis of age group, ADHD has been segmented into pediatric, adolescent and adult and the major distribution channels for ADHD are retail pharmacy and hospital pharmacy.

The global attention-deficit hyperactivity disorder (ADHD) market has witnessed continuous growth in the past few years and is projected to grow even further during the forecast period (2019-2023). The market is expected to be driven by various growth enhancing factors such as rising healthcare expenditure, excessive use of smartphones, increasing investments in mental health technology, growing impact of social media, etc. Some of the major challenges faced by the market are misuse of drugs used in the treatment of ADHD and high cost of ADHD treatment.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H2 2019

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Neuromyelitis Optica - Pipeline Review, H2 2019, provides an overview ...

Restless Legs Syndrome - Pipeline Review, H2 2019

Restless Legs Syndrome - Pipeline Review, H2 2019

  • $ 2000
  • August 2019

Restless Legs Syndrome - Pipeline Review, H2 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Restless Legs Syndrome - Pipeline Review, H2 2019, provides ...

Glutamate Receptor Ionotropic NMDA 2B - Pipeline Review, H2 2019

Glutamate Receptor Ionotropic NMDA 2B - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

Glutamate Receptor Ionotropic NMDA 2B - Pipeline Review, H2 2019SummaryAccording to the recently published report ’Glutamate Receptor Ionotropic NMDA 2B - Pipeline Review, H2 2019’; Glutamate Recepto ...


ref:plp2019

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on